Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2023 / Articles / Jul / Video: Josh Ludwig Talks Manufacturing in the Cell and Gene Industry
Manufacture Advanced Medicine Drug Discovery Formulation Trends & Forecasts Drug Discovery Research News Formulation Business & Trends

Video: Josh Ludwig Talks Manufacturing in the Cell and Gene Industry

We interviewed ScaleReady’s Global Commercial Director Josh Ludwig to learn more about manufacturing in the cell and gene Industry

By Jamie Irvine 08/01/2023 1 min read

Share

Manufacturing, manufacturing, manufacturing! Check out our latest video interview with Josh Ludwig, Global Commercial Director for ScaleReady, who joined us from the ISCT 2023 convention in Paris. Ludwig discusses growth prospects in the cell and gene space, and forecasts avenues for future development.

Josh Ludwig leads commercial operations as the global director for ScaleReady. He closely collaborates with the EMEA commercial and leadership teams to ensure ScaleReady addresses the long standing industry need for a truly scalable and practical solution. Josh has more than a decade of experience in commercial leadership and business development in the medical device industry with a specific focus on engaging directly with customers and achieving customer and company goals.  

Before ScaleReady, Josh spent more than seven years supporting technical and business development at Wilson Wolf, a founding partner of ScaleReady. He successfully established protocols and executed all aspects of global business development, customer service, and marketing efforts. Josh’s career in Life Sciences began by obtaining a Bachelor of Science in biology and a minor in chemistry from the University of St. Thomas.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jamie Irvine

Associate Editor, The Medicine Maker

More Articles by Jamie Irvine

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.